Answers are grounded in this paper and cite their sources.
Genomic analysis has the potential to both risk-stratify and inform management of patients diagnosed with large B-cell lymphomas (LBCL). We analyzed cases of patients with newly diagnosed LBCL treated with standard immunochemotherapy from three publicly available cohorts of patients on which FISH and next-generation sequencing were performed to determine the frequency of genomic alterations based upon the development of disease progression. Cases from 698 patients were analyzed, with 201 experiencing disease progression and 497 experiencing no disease progression by 24 months after diagnosis. When analyzing for the presence of MYC rearrangement and MYC–BCL2 dual-rearrangement/double-hit status, as well as variants predicted to result in alterations in protein function in 15 genes common to next-generation sequencing panels from all three cohorts, only MYC rearrangement and TP53 mutation were associated with significantly higher odds of disease progression on multivariate analysis. Additionally, cases from patients who experienced disease progression demonstrated a high frequency of specific genomic alterations when analyzed by cohort or cell-of-origin classification by IHC when available. Individual genomic features of LBCL cases may predict for the development of disease progression in newly diagnosed patients treated with standard therapies, as well as occur at higher frequencies in cases of disease progression based upon geographic region and/or cell-of-origin status. These novel findings support efforts to evaluate genomic features as biomarkers for response to specific therapies in subsets of patients with LBCL who experience disease progression, which may lead to discovery of more effective treatment options. Significance: Genomic features of LBCL that can be detected by clinical laboratory assays may predict for resistance to first-line immunochemotherapy, as well as support the exploration of genomic features as biomarkers of response to therapies which could be offered to patients who experience disease progression.
No takes yet. Share an insight, caveat, or question.
Landsburg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: